Literature DB >> 3264530

Clonal analysis of human T cell activation by the Mycoplasma arthritidis mitogen (MAS).

M Matthes1, H Schrezenmeier, J Homfeld, S Fleischer, B Malissen, H Kirchner, B Fleischer.   

Abstract

Mycoplasma arthritidis produces an as yet undefined soluble molecule (MAS) that has a potent mitogenic effect on T cells of several species. We have used cloned human cytotoxic and proliferative T lymphocytes to dissect the molecular mechanism of T cell activation by this mitogen. Reactivity to MAS is clonally expressed among T cell receptor (TcR) alpha/beta chain-expressing T cell clones of CD4+ or CD8+ phenotype, as well as CD4-8- TcR alpha/beta chain-negative T lymphocyte clones expressing the CD3-associated TcR gamma chain. MAS is able to induce cytotoxicity and/or proliferation in these T cell clones. For triggering of these T cells, regardless of their phenotype of specificity, the presence of autologous, allogeneic or xenogeneic major histocompatibility complex (MHC) class II molecules on accessory cells or target cells is necessary. However, T cells do not immunologically recognize MAS on class II molecules, since a direct action of MAS on the T cells themselves can be demonstrated. Triggering of T cells by MAS can be blocked by monoclonal antibodies against CD2, CD3 and the TcR alpha/beta chain dimer. We discuss as a possible explanation that MAS is a functionally bivalent molecule cross-linking TcR and MHC class II molecules. Thus, the mechanism of T cell activation by MAS has striking similarities to the mechanisms by which Staphylococcal enterotoxins activate T cells. It is intriguing that a similar mitogenic principle has been developed by two evolutionary distinct pathogenic microorganisms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264530     DOI: 10.1002/eji.1830181112

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

1.  Conventional antigen and superantigen may be coupled to distinct and cooperative T-cell activation pathways.

Authors:  H Liu; M A Lampe; M V Iregui; H Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

2.  Crystal structure of a complete ternary complex of TCR, superantigen and peptide-MHC.

Authors:  Limin Wang; Yiwei Zhao; Zhong Li; Yi Guo; Lindsay L Jones; David M Kranz; Walid Mourad; Hongmin Li
Journal:  Nat Struct Mol Biol       Date:  2007-01-14       Impact factor: 15.369

Review 3.  T lymphocyte-stimulating microbial toxins as "superantigens".

Authors:  B Fleischer
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

Review 4.  Microbial "superantigens".

Authors:  M L Misfeldt
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

Review 5.  Role of superantigens in experimental arthritis.

Authors:  A Abdelnour; Y X Zhao; T Bremell; R Holmdahl; A Tarkowski
Journal:  Springer Semin Immunopathol       Date:  1996

Review 6.  The role of leukocyte adhesion molecules in cellular interactions: implications for the pathogenesis of inflammatory synovitis.

Authors:  B F Haynes; L P Hale; S M Denning; P T Le; K H Singer
Journal:  Springer Semin Immunopathol       Date:  1989

7.  Mycoplasma arthritidis-derived superantigen induces proinflammatory monokine gene expression in the THP-1 human monocytic cell line.

Authors:  R al-Daccak; K Mehindate; J Hébert; L Rink; S Mecheri; W Mourad
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

8.  Differential induction of tumor necrosis factor alpha in murine and human leukocytes by Mycoplasma arthritidis-derived superantigen.

Authors:  L Rink; W Nicklas; L Alvarez-Ossorio; M Koester; H Kirchner
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

Review 9.  Molecular biology and pathogenicity of mycoplasmas.

Authors:  S Razin; D Yogev; Y Naot
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

10.  Macrophage-activating factor extracted from mycoplasmas.

Authors:  M Takema; S Oka; K Uno; S Nakamura; H Arita; K Tawara; K Inaba; S Muramatsu
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.